Implementation of patient-reported outcome measures in real-world evidence studies : Analysis of ClinicalTrials.gov records (1999-2021)
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Real-world evidence (RWE) plays an increasingly important role within global regulatory and reimbursement processes. RWE generation can be enhanced by collecting and using patient-reported outcomes (PROs), which can provide valuable information on the effectiveness, safety, and tolerability of health interventions from the patient perspective. This analysis aims to examine and summarise the utilisation of patient-reported outcomes measures (PROMs) in real-world studies.
METHODS: Descriptions of phase IV trials were downloaded on July 22, 2021 from the Clinicaltrials.gov database since its inception. An automated algorithm was built to detect trials utilising PROMs and composite measures including patient-reported components. Search terms were developed based on the PROQOLID database.
RESULTS: Of 27,976 phase IV clinical trials posted on Clinicaltrials.gov between 1999 and July 2021, 21% and 4% used PROMs and composite measures, respectively. Recent years demonstrated a steady increase in the utilisation of PROMs in phase IV trials.
CONCLUSIONS: The use of PROMs in phase IV trials seems to be lower than its use in earlier phases of clinical research. Increased uptake of PROMs in RWE studies can be facilitated in a number of ways including the development of standards for their collection, analysis and use.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:120 |
|---|---|
| Enthalten in: |
Contemporary clinical trials - 120(2022) vom: 03. Sept., Seite 106882 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Maruszczyk, Konrad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical trial |
|---|
| Anmerkungen: |
Date Completed 23.09.2022 Date Revised 23.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cct.2022.106882 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344923223 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344923223 | ||
| 003 | DE-627 | ||
| 005 | 20240229143556.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cct.2022.106882 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1303.xml |
| 035 | |a (DE-627)NLM344923223 | ||
| 035 | |a (NLM)35973663 | ||
| 035 | |a (PII)S1551-7144(22)00208-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Maruszczyk, Konrad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Implementation of patient-reported outcome measures in real-world evidence studies |b Analysis of ClinicalTrials.gov records (1999-2021) |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.09.2022 | ||
| 500 | |a Date Revised 23.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Real-world evidence (RWE) plays an increasingly important role within global regulatory and reimbursement processes. RWE generation can be enhanced by collecting and using patient-reported outcomes (PROs), which can provide valuable information on the effectiveness, safety, and tolerability of health interventions from the patient perspective. This analysis aims to examine and summarise the utilisation of patient-reported outcomes measures (PROMs) in real-world studies | ||
| 520 | |a METHODS: Descriptions of phase IV trials were downloaded on July 22, 2021 from the Clinicaltrials.gov database since its inception. An automated algorithm was built to detect trials utilising PROMs and composite measures including patient-reported components. Search terms were developed based on the PROQOLID database | ||
| 520 | |a RESULTS: Of 27,976 phase IV clinical trials posted on Clinicaltrials.gov between 1999 and July 2021, 21% and 4% used PROMs and composite measures, respectively. Recent years demonstrated a steady increase in the utilisation of PROMs in phase IV trials | ||
| 520 | |a CONCLUSIONS: The use of PROMs in phase IV trials seems to be lower than its use in earlier phases of clinical research. Increased uptake of PROMs in RWE studies can be facilitated in a number of ways including the development of standards for their collection, analysis and use | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Clinical trial | |
| 650 | 4 | |a PRO | |
| 650 | 4 | |a PROM | |
| 650 | 4 | |a Phase IV | |
| 650 | 4 | |a RWD | |
| 650 | 4 | |a RWE | |
| 700 | 1 | |a Aiyegbusi, Olalekan Lee |e verfasserin |4 aut | |
| 700 | 1 | |a Cardoso, Victor Roth |e verfasserin |4 aut | |
| 700 | 1 | |a Gkoutos, Georgios V |e verfasserin |4 aut | |
| 700 | 1 | |a Slater, Karin |e verfasserin |4 aut | |
| 700 | 1 | |a Collis, Philip |e verfasserin |4 aut | |
| 700 | 1 | |a Keeley, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Calvert, Melanie J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Contemporary clinical trials |d 2005 |g 120(2022) vom: 03. Sept., Seite 106882 |w (DE-627)NLM154869031 |x 1559-2030 |7 nnns |
| 773 | 1 | 8 | |g volume:120 |g year:2022 |g day:03 |g month:09 |g pages:106882 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cct.2022.106882 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 120 |j 2022 |b 03 |c 09 |h 106882 | ||